Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 5/20 | 0.74 |
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.73 |
| ▸ | MEN1 | O00255 | 8/20 | 0.73 |
| ▸ | RAB9A | P51151 | 8/20 | 0.73 |
| ▸ | MAPT | P10636 | 6/20 | 0.73 |
| ▸ | NPC1 | O15118 | 5/20 | 0.73 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.72 |
| ▸ | GAA | P10253 | 4/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.72 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.72 |
| ▸ | RELA | Q04206 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.72 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.70 |
| ▸ | VCP | P55072 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1819906 | 0.94 | RAB9A (0.78) | ALOX5AMY1AKMT2AMEN1RAB9A | |
| SCHEMBL17320209 | 0.92 | ALOX5 (0.85) | ALOX5AMY1AKMT2AMEN1RAB9A | |
| SCHEMBL7554523 | 0.92 | ALOX5 (0.84) | ALOX5AMY1AKMT2AMEN1RAB9A | |
| Bromide SCHEMBL7670429 | 0.90 | ALOX5 (0.82) | ALOX5AMY1AKMT2AMEN1RAB9A | |
| SCHEMBL1822611 | 0.89 | SMN1; SMN2 (0.84) | ALOX5AMY1AKMT2AMEN1RAB9A | |
| SCHEMBL12298108 | 0.85 | MEN1 (0.78) | ALOX5AMY1AKMT2AMEN1RAB9A | |
| SCHEMBL1821894 | 0.85 | ALOX5 (0.79) | ALOX5AMY1AKMT2AMEN1RAB9A | |
| SCHEMBL12297401 | 0.85 | ALOX5 (0.74) | ALOX5AMY1AKMT2AMEN1RAB9A | |
| SCHEMBL838274 | 0.85 | ALOX5 (0.74) | ALOX5AMY1AKMT2AMEN1RAB9A | |
| SCHEMBL12297429 | 0.85 | ALOX5 (0.74) | ALOX5AMY1AKMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486872-A | Mechanical ball milling synthesis method of aminothiazole compound | 浙江工业大学 | 2024-02-02 | — | — | CN | disclosed |
| US-20210299131-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NATIONAL INSTITUTES OF HEALTH | 2021-09-30 | — | — | US | disclosed |
| US-10953017-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200171040-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RES INST (US) | 2020-06-04 | — | — | US | disclosed |
| US-20190083505-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NATIONAL INSTITUTES OF HEALTH | 2019-03-21 | — | — | US | disclosed |
| US-9980969-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2018-05-29 | — | — | US | disclosed |
| US-9980969-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2018-05-29 | — | — | US | disclosed |
| US-20160022691-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RES INST (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160022691-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RES INST (US) | 2016-01-28 | — | — | US | disclosed |
| US-9095596-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2015-08-04 | — | — | US | disclosed |
| US-20120245166-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RESEARCH INSTITUTE (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245166-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RESEARCH INSTITUTE (US) | 2012-09-27 | — | — | US | disclosed |
| US-8119680-B2 | α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| WO-2011047129-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RESEARCH INSTITUTE (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20100331551-A1 | ALPHA-HALOKETONE DERIVATIVES OF IMIDAZOLYL-SUBSTITUTED AROMATIC COMPOUNDS AND COMPOUNDS PREPARED THEREFROM | NEUROGENETIC PHARMACEUTICALS, INC | 2010-12-30 | — | — | US | disclosed |
| US-7799808-B2 | α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7781442-B2 | Compounds and uses thereof in modulating amyloid beta | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | TORREYPINES THERAPEUTICS INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | TORREYPINES THERAPEUTICS INC. | 2007-10-25 | — | — | US | disclosed |
| US-7244739-B2 | Compounds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022691-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | ALOX5 330/4885AMY1A 1075/4885KMT2A 1669/4885 |
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | APP, BACE1, BACE2 | ALOX5 1213/4885AMY1A 169/4885KMT2A 3770/4885 |
| US-20200171040-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | ALOX5 304/4885AMY1A 1183/4885KMT2A 1656/4885 |
| US-20190083505-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | ALOX5 304/4885AMY1A 1183/4885KMT2A 1656/4885 |
| US-20100331551-A1 | ALPHA-HALOKETONE DERIVATIVES OF IMIDAZOLYL-SUBSTITUTED AROMATIC COMPOUNDS AND COMPOUNDS PREPARED THEREFROM | HYPK, APP, NEFM | ALOX5 4500/4885AMY1A 384/4885KMT2A 2363/4885 |
| US-20210299131-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | ALOX5 304/4885AMY1A 1183/4885KMT2A 1656/4885 |
| US-20120245166-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | ALOX5 304/4885AMY1A 1183/4885KMT2A 1656/4885 |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | PSEN2, APP, BACE1 | ALOX5 3224/4885AMY1A 109/4885KMT2A 1829/4885 |
| US-10953017-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | NFKBIA, NFRKB, TFEB | ALOX5 304/4885AMY1A 1183/4885KMT2A 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.